Clinical trials registration
Not applicable. This was a demonstration project for CMS, not a clinical
trial.
1. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of
people with sickle-cell disease in the United States: national and state
estimates. Am J Hematol . Jan 2010;85(1):77-8.
doi:10.1002/ajh.21570
2. Hassell KL. Population estimates of sickle cell disease in the U.S.Am J Prev Med . Apr 2010;38(4 Suppl):S512-21.
doi:10.1016/j.amepre.2009.12.022
3. Brodsky MA, Rodeghier M, Sanger M, et al. Risk Factors for 30-Day
Readmission in Adults with Sickle Cell Disease. Am J Med . May
2017;130(5):601 e9-601 e15. doi:10.1016/j.amjmed.2016.12.010
4. Cronin RM, Dorner TL, Utrankar A, et al. Increased Patient Activation
Is Associated with Fewer Emergency Room Visits and Hospitalizations for
Pain in Adults with Sickle Cell Disease. Pain Med . Aug 1
2019;20(8):1464-1471. doi:10.1093/pm/pny194
5. Cronin RM, Yang M, Hankins JS, et al. Association between hospital
admissions and healthcare provider communication for individuals with
sickle cell disease. Hematology . Dec 2020;25(1):229-240.
doi:10.1080/16078454.2020.1780737
6. Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
Outcomes, utilization, and costs among thalassemia and sickle cell
disease patients receiving deferoxamine therapy in the United States.Am J Hematol . Apr 2008;83(4):263-70. doi:10.1002/ajh.21049
7. Gehrie EA, Ness PM, Bloch EM, Kacker S, Tobian AAR. Medical and
economic implications of strategies to prevent alloimmunization in
sickle cell disease. Transfusion . Sep 2017;57(9):2267-2276.
doi:10.1111/trf.14212
8. Kamble S, Telen MJ, Dinan MA, Grussemeyer CA, Reed SD. Costs and
length of stay for patients with and without sickle cell disease after
hysterectomy, appendectomy, or knee replacement. Am J Hematol .
Jan 2010;85(1):79-81. doi:10.1002/ajh.21576
9. Weatherall D, Hofman K, Rodgers G, Ruffin J, Hrynkow S. A case for
developing North-South partnerships for research in sickle cell disease.Blood . Feb 1 2005;105(3):921-3. doi:10.1182/blood-2004-06-2404
10. Gupta N, Mocumbi A, Arwal SH, et al. Prioritizing Health-Sector
Interventions for Noncommunicable Diseases and Injuries in Low- and
Lower-Middle Income Countries: National NCDI Poverty Commissions.Glob Health Sci Pract . Sep 30 2021;9(3):626-639.
doi:10.9745/GHSP-D-21-00035
11. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev
Dis Primers . Mar 15 2018;4:18010. doi:10.1038/nrdp.2018.10
12. Chang AK, Ginter Summarell CC, Birdie PT, Sheehan VA. Genetic
modifiers of severity in sickle cell disease. Clin Hemorheol
Microcirc . 2018;68(2-3):147-164. doi:10.3233/CH-189004
13. Hsu LL, Green NS, Donnell Ivy E, et al. Community Health Workers as
Support for Sickle Cell Care. Am J Prev Med . Jul 2016;51(1 Suppl
1):S87-98. doi:10.1016/j.amepre.2016.01.016
14. Peterson EE, Salemi JL, Dongarwar D, Salihu HM. Acute care
utilization in pediatric sickle cell disease and sickle cell trait in
the USA: prevalence, temporal trends, and cost. Eur J Pediatr .
Nov 2020;179(11):1701-1710. doi:10.1007/s00431-020-03656-x
15. Shah N, Bhor M, Xie L, Paulose J, Yuce H. Medical Resource Use and
Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A
Retrospective Claims Study. J Health Econ Outcomes Res .
2020;7(1):52-60. doi:10.36469/jheor.2020.12852
16. Habara A, Steinberg MH. Minireview: Genetic basis of heterogeneity
and severity in sickle cell disease. Exp Biol Med (Maywood) . Apr
2016;241(7):689-96. doi:10.1177/1535370216636726
17. Saraf SL, Akingbola TS, Shah BN, et al. Associations of
alpha-thalassemia and BCL11A with stroke in Nigerian, United States, and
United Kingdom sickle cell anemia cohorts. Blood Adv . Apr 25
2017;1(11):693-698. doi:10.1182/bloodadvances.2017005231
18. Marshall K, Howell S, Badaloo A, Reid M, McFarlane-Anderson N,
McKenzie C. Exploring putative genetic determinants of inter-individual
phenotypic heterogeneity in sickle cell disease: A cross-sectional
Jamaican cohort-based study. Blood Cells Mol Dis . Nov
2018;73:1-8. doi:10.1016/j.bcmd.2018.08.001
19. Brennan-Cook J, Bonnabeau E, Aponte R, Augustin C, Tanabe P.
Barriers to Care for Persons With Sickle Cell Disease: The Case
Manager’s Opportunity to Improve Patient Outcomes. Prof Case
Manag . Jul/Aug 2018;23(4):213-219. doi:10.1097/ncm.0000000000000260
20. Edge NB. Breaking the Cycle: Care Coordination Interventions and
Sickle Cell Readmissions. Prof Case Manag . Jan-Feb 01
2022;27(1):12-18. doi:10.1097/NCM.0000000000000526
21. Glassberg JA, Wang J, Cohen R, Richardson LD, DeBaun MR. Risk
factors for increased ED utilization in a multinational cohort of
children with sickle cell disease. Acad Emerg Med . Jun
2012;19(6):664-72. doi:10.1111/j.1553-2712.2012.01364.x
22. Hsu LL, Fan-Hsu J. Evidence-based dental management in the new era
of sickle cell disease: A scoping review. J Am Dent Assoc . Sep
2020;151(9):668-677 e9. doi:10.1016/j.adaj.2020.05.023
23. Glassgow AE, Martin MA, Caskey R, et al. An innovative health-care
delivery model for children with medical complexity. J Child
Health Care . Sep 2017;21(3):263-272. doi:10.1177/1367493517712063
24. Tyris J, Keller S, Parikh K. Social Risk Interventions and Health
Care Utilization for Pediatric Asthma: A Systematic Review and
Meta-analysis. JAMA Pediatr . Feb 1 2022;176(2):e215103.
doi:10.1001/jamapediatrics.2021.5103
25. Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. Environmental
determinants of severity in sickle cell disease. Haematologica .
Sep 2015;100(9):1108-16. doi:10.3324/haematol.2014.120030
26. Piel FB, Tewari S, Brousse V, et al. Associations between
environmental factors and hospital admissions for sickle cell disease.Haematologica . Apr 2017;102(4):666-675.
doi:10.3324/haematol.2016.154245
27. Jonassaint CR, Jones VL, Leong S, Frierson GM. A systematic review
of the association between depression and health care utilization in
children and adults with sickle cell disease. Br J Haematol . Jul
2016;174(1):136-47. doi:10.1111/bjh.14023
28. Gustafson EL, Lakind D, Walden AL, Rusch D, Atkins MS. Engaging
Parents in Mental Health Services: A Qualitative Study of Community
Health Workers’ Strategies in High Poverty Urban Communities. Adm
Policy Ment Health . Nov 2021;48(6):1019-1033.
doi:10.1007/s10488-021-01124-8
29. Martin MA, Collazo GR, Frese WA, Glassgow AE. Oral Health Problems
and Solutions in High-Risk Children and Young Adults. J Dent Child
(Chic) . Sep 15 2018;85(3):125-132.
30. Minier M, Hirshfield L, Ramahi R, Glassgow AE, Fox K, Martin MA.
Schools and Health: An Essential Partnership for the Effective Care of
Children with Chronic Conditions. J Sch Health . Sep
2018;88(9):699-703. doi:10.1111/josh.12671
31. Martin MA, Perry-Bell K, Minier M, Glassgow AE, Van Voorhees BW. A
Real-World Community Health Worker Care Coordination Model for High-Risk
Children. Health Promot Pract . May 2019;20(3):409-418.
doi:10.1177/1524839918764893
32. Bansa M, Glassgow AE, Martin M, et al. Development of a
Community-Based Medical Neighborhood for Children with Chronic
Conditions. Prog Community Health Partnersh . 2019;13(1):83-95.
doi:10.1353/cpr.2019.0011
33. Caskey R, Moran K, Touchette D, et al. Effect of Comprehensive Care
Coordination on Medicaid Expenditures Compared With Usual Care Among
Children and Youth With Chronic Disease: A Randomized Clinical Trial.JAMA Netw Open . Oct 2 2019;2(10):e1912604.
doi:10.1001/jamanetworkopen.2019.12604
34. Glassgow AE, Gerges M, Atkins M, et al. Exploring Racial Disparities
in Mental Health Diagnoses and Neighborhood Disorganization Among an
Urban Cohort of Children and Adolescents with Chronic Medical
Conditions. Health Equity . 2019;3(1):604-611.
doi:10.1089/heq.2019.0085
35. Deb P, Norton EC. Modeling Health Care Expenditures and Use.Annu Rev Public Health . Apr 1 2018;39:489-505.
doi:10.1146/annurev-publhealth-040617-013517
36. Molenberghs G, Verbeke G. Models for Discrete Longitudinal
Data . 1 ed. Springer Series in Statistics. Springer; 2005:687.
37. Piulachs X, Andrinopoulou ER, Guillen M, Rizopoulos D. A Bayesian
joint model for zero-inflated integers and left-truncated event times
with a time-varying association: Applications to senior health care.Stat Med . Jan 15 2021;40(1):147-166. doi:10.1002/sim.8767
38. Dunnett CW. A multiple comparison procedure for comparing several
treatments with a control. Journal of the American Statistical
Association . 1955;50(272):1096-1121.
39. Holdford D, Vendetti N, Sop DM, Johnson S, Smith WR. Indirect
Economic Burden of Sickle Cell Disease. Value Health . Aug
2021;24(8):1095-1101. doi:10.1016/j.jval.2021.02.014
40. Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu A. Lifetime
medical costs attributable to sickle cell disease among nonelderly
individuals with commercial insurance. Blood Adv . May 16
2022;doi:10.1182/bloodadvances.2021006281
41. Raphael JL, Dietrich CL, Whitmire D, Mahoney DH, Mueller BU,
Giardino AP. Healthcare utilization and expenditures for low income
children with sickle cell disease. Pediatr Blood Cancer . Feb
2009;52(2):263-7. doi:10.1002/pbc.21781
42. Rattler TL, Walder AM, Feng H, Raphael JL. Care Coordination for
Children With Sickle Cell Disease: A Longitudinal Study of Parent
Perspectives and Acute Care Utilization. Am J Prev Med . Jul
2016;51(1 Suppl 1):S55-61. doi:10.1016/j.amepre.2016.01.023
43. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle
cell disease: summary of the 2014 evidence-based report by expert panel
members. JAMA . Sep 10 2014;312(10):1033-48.
doi:10.1001/jama.2014.10517